Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
1
Study Matches
A Phase 3, randomized, double-blind, parallel-group, placebo-controlled multicenter study to evaluate the efficacy and safety
of two doses of GLPG1690 in addition to local standard of care
for minimum 52 weeks in subjects with idiopathic pulmonary
fibrosis
This study is for patients with IPF (Idiopathic Pulmonary Fibrosis) to see how well a new medication works with current standard treatment on lung function and IPF disease in general.
Age 40 or greater Diagnosis of Idiiopathic Pulmonary Fibrosis (IPF) within the past 5 years
Exclusion Criteria:
HIV or hepatitis B or C diagnosis History of malignancy within the past 5 years Acute IPF reoccurrence in the past 6 months Lower respiratory tract infection in the past 4 weeks requiring antibiotics History of lung volume reduction surgery or lung transplant